NASDAQ$GNLX
Genelux Corporation · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Genelux reported Q3 2025, net loss of $8M.
For Q3 2025, Genelux reported a net loss of $8M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Net loss $8M.
- Genelux MD&A covers liquidity, credit, and operating priorities.
- Genelux MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Genelux · Revenue · Quarterly
$0
Forward guidance
Clinical-stage biotech outlook centers on trial milestones, partnerships, and cash runway.
Tailwinds
- Pipeline milestones and collaboration optionality.
- Cash funds operations.
Headwinds
- Trial delay or failure risk.
- Future financing dilution.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2025
-4.7%
Avg return
Earnings day
-5.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
31%
5 / 16 earnings
Positive
+4.7%
Q2 2023
Best reaction
-31.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | +12.1% | +3.9% | |
| Q3 2025 | -31.4% | -23.7% | -40.8% | |
| Q2 2025 | -6.0% | -4.2% | +0.9% | |
| Q1 2025 | +4.5% | +0.4% | +30.2% | |
| Q4 2024 | -4.4% | -11.5% | -10.2% | |
| Q3 2024 | -16.0% | -11.7% | -17.1% | |
| Q2 2024 | +3.4% | +1.5% | +18.4% | |
| Q1 2024 | +1.1% | -5.5% | -39.8% | |
| Q4 2023 | -18.4% | -23.3% | -49.0% | |
| Q3 2023 | -4.8% | -16.2% | +4.6% | |
| Q3 2022 | -4.8% | -16.2% | +4.6% | |
| Q2 2022 | +4.7% | +3.6% | -8.6% | |
| Q2 2023 | +4.7% | +3.6% | -8.6% | |
| Q4 2022 | -0.4% | +3.4% | +33.6% | |
| Q1 2022 | -0.4% | +3.4% | +33.6% | |
| Q1 2023 | -0.4% | +3.4% | +33.6% | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro